AT1 receptor antagonists: A challenge for ACE inhibitors in diabetic nephropathy

Diabetes/Metabolism Research and Reviews

Volumn 15, Issue 1, 1999, Pages 55-58

  Mogyorósi, András ^a,c   Sonkodi, Sándor ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF SZEGED   (Hungary)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitors; Angiotensin II; Angiotensin II Type 1 receptor antagonists; Diabetic nephropathy; Treatment

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFICACY; GLOMERULOSCLEROSIS; GROWTH; HEMODYNAMICS; KIDNEY HYPERTROPHY; METABOLISM; MICROALBUMINURIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETIC NEPHROPATHIES; HUMANS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN;

EID: 0344223289     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-7560(199901/02)15:1<55::AID-DMRR12>3.0.CO;2-6     Document Type: Short Survey

References (23)

1. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-1407.
2. Mann J, Ritz E. The renin-angiotensin system in diabetic patients. Klin Wochenschr 1988; 66: 883-891.
3. Wolf G, Ziyadeh FN. The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 1997; 29: 153-163.
4. Ritz E, Nowack R. Preservation of renal function in diabetic patients. J Cardiovasc Pharmacol 1991; 18 (Suppl 2): S54-S58.
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
6. Ravid M, Savin H, Jutrin I, Bental T, Lang R. Longterm effect of ACE inhibition on development of nephropathy in diabetes mellitus Type II. Kidney Int 1994; 45: S161-S164.
7. Parving HH, Rossing P, Hommel E, Smidt UM. Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience. Am J Kidney Dis 1995; 26: 99-107.
8. Mogensen CE. Diabetic renal disease: the quest for normotension - and beyond. Diabet Med 1995; 12: 756-769.
9. Hollenberg NK. ACE inhibitors, ATI receptor blockers, and the kidney. Nephrol Dial Transplant 1997; 12: 381-383.
10. Allen TJ, Cao Z, Youssef S, Hulthen UL, Cooper ME. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Diabetes 1997; 46: 1612-1618.
11. Villa E, Rabano A, Gazes M, Cloarec A, Ruilope LM, Garcia-Robles R. Effects of UP269-6, a new angiotensin II receptor antagonist, and captopril on the progression of rat diabetic nephropathy. Am J Hypertens 1997; 10: 275-281.
12. Chan JC, Critchley JA, Tomlinson B, Chan TY, Cockram CS. Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 1997; 17: 72-80.
13. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861-867.
14. Nielsen S, Dollerup J, Nielsen B, Jensen MA, Mogensen CA. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant 1997; 12 (Suppl 2): 19-23.
15. Chung O, Unger T. Unopposed stimulation of the angiotensin AT2 receptor in the kidney. Nephrol Dial Transplant 1998; 3: 537-540.
16. Yotsumoto T, Naitoh T, Shikada K, Tanaka S. Effects of specific antagonists of angiotensin II receptors and captopril on diabetic nephropathy in mice. Jap J Pharmacol 1997; 75: 59-64.
17. Price DA, De'Oliveira JM, Fisher NDL, Hollenberg NK. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension 1997; 30: 240-246.
18. Fisher NDL, Allan D, Kifor I, Gaboury CL, Williams GH, Moore TJ, Hollenberg NK. Responses to converting enzyme and renin inhibition: role of angiotensin II in humans. Hypertension 1994; 23: 44-51.
19. Mogyorósi A, Ziyadeh FN. Update on pathogenesis, markers, and management of diabetic nephropathy. Curr Op Nephrol Hypertension 1996; 5: 243-253.
20. Moan A, Risanger T, Eide I, Kjeldsen SE. The effect of angiotensin II blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 1994; 3: 185-188.
21. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.
22. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91: 1269-1281.
23. Murakami M, Matsuda H, Kubota E, Wakino S, Honda M, Hayashi K, Saruta T. Role of angiotensin II generated by angiotensin converting enzyme-independent pathways in canine kidney. Kidney Int 1997; 63 (Suppl): S132-S135.